

## Freedom of Information Request: Our Reference CTMUHB\_184\_22

### You asked:

I am analysing the usage of **intra-vitreous injections or implants** by the NHS. I would greatly appreciate if you could answer the following questions:

1. How many of the following intra-vitreous injections/implants has your Health Board administered in the four-month period from January to April 2022:

- Aflibercept
- Bevacizumab
- Brolucizumab
- Dexamethasone
- Fluocinolone acetonide
- Ranibizumab

2. Please provide the number of injections/implants by eye condition for the four-month period from January to April 2022.

### Number of Injections/Implants: Jan to Apr 2022

Treatment	Eye Conditions		
	Wet Age-Related Macular Degeneration wAMD	Diabetic Macular Degeneration DMO	Retinal Vein Occlusion RVO
Aflibercept			
Bevacizumab			
Brolucizumab			
Dexamethasone			
Fluocinolone acetonide			
Ranibizumab			

### Our response:

Please see the populated table provided below, with data that Medicines Management are able to provide in relation to Q1 & Q2. The data period relates to 1<sup>st</sup> January 22 to 30<sup>th</sup> April 22 as requested.

Treatment	Total	Eye Conditions			
		Wet Age-Related Macular Degeneration wAMD	Diabetic Macular Degeneration DMO	Retinal Vein Occlusion RVO	Condition Not Known
Aflibercept	1638	1149	245	244	
Bevacizumab	26				26
Brolucizumab	0				
Dexamethasone	51				51
Fluocinolone acetonide	0				
Ranibizumab	18	6	**	**	7

Where the figures are less than 5, this has been denoted by \*\*. The exact figures have been withheld due to the low numbers involved.

Where numbers are low we have considered that there is the potential for the individuals to be identified from the information provided, when considered with other information that may also be in the public domain. Also, responses under the Freedom of Information Act are made available to the public at large. The data is classed as personal data as defined under the General Data Protection Regulation (GDPR) and Data Protection Act 2018 and its disclosure would be contrary to the data protection principles and constitute as unfair and unlawful processing in regard to Articles 5, 6, and 9 of GDPR. We are therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000. This exemption is absolute and therefore there is no requirement to apply the public interest test.